Nektar Therapeutics Initiates Phase 3 BEACON Trial of NKTR102 in Women with...
SAN FRANCISCO Dec. 12 2011 PRNewswire Nektar Therapeutics Nasdaq NKTR announced today that the company has initiated its pivotal Phase 3 global clinical trial evaluating NKTR102 as a single agent in...
View ArticleSeres Therapeutics Reports Positive Topline Results from SER287 Phase 1b...
SER287 microbiome treatment resulted in a dosedependent benefit in clinical remission rates and an improvement in endoscopic scores No clinically significant safety or tolerability findings were...
View ArticleNektar Announces Positive Clinical Data from Second Phase 1 Clinical Study of...
&160; SAN FRANCISCO Dec. 13 2011 PRNewswire &160;Nektar Therapeutics Nasdaq NKTR today announced positive data from a Phase 1 clinical study of NKTR181 evaluating multiple ascending oral doses...
View ArticleRedHill Biopharma Accelerates RHB104 Phase III Study in Crohns Disease with...
RedHill has curtailed the target sample size in the ongoing first Phase III study with RHB104 for Crohns disease MAP US from 410 to approximately 325 subjects of which 322 have been enrolled to date...
View ArticleCORRECTING and REPLACING Seres Therapeutics Reports Positive Topline Results...
SER287 microbiome treatment resulted in a dosedependent benefit in clinical remission rates and an improvement in endoscopic scores No clinically significant safety or tolerability findings were...
View ArticleCoronado Biosciences Announces Phase 1 Results of CNDO109 in AML Presented at...
BURLINGTON Mass. Dec.&160;13 2011 PRNewswire &160;Coronado Biosciences Inc. OTCBB CNDO a biopharmaceutical company focused on the development of novel immunotherapy agents for the treatment of...
View ArticleRedHill Biopharma Accelerates RHB104 Phase III Study in Crohn's Disease with...
RedHill has curtailed the target sample size in the ongoing first Phase III study with RHB104 for Crohn's disease MAP US from 410 to approximately 325 subjects of which 322 have been enrolled...
View ArticleSoligenix Initiates Next Generation Anthrax Vaccine Development Program Under...
PRINCETON N.J. Dec. 15 2011 PRNewswire &160;Soligenix Inc. OTCBB SNGX Soligenix or the Company a development stage biopharmaceutical company announced today that it has initiated a next generation...
View ArticleForbes Ranks HealthWell Foundation One of America's Most Efficient Charities
GAITHERSBURG Md. Dec.&160;15 2011 PRNewswire &160;The HealthWell Foundation&174; a national nonprofit providing financial assistance to insured individuals with high outofpocket medication...
View ArticleThe Kenneth Rainin Foundation Announces 2012 Innovations Symposium New...
OAKLAND Calif. Dec. 19 2011 PRNewswireUSNewswire The Kenneth Rainin Foundation announced today its inaugural 2012 Innovations Symposium which will be held on Friday July 20 2012 at The Four Seasons...
View ArticleSelexys Pharmaceuticals Completes Phase I Clinical Study for Sickle Cell Drug
OKLAHOMA CITY Dec. 19 2011 PRNewswire Selexys Pharmaceuticals announced today that it has completed a Phase I clinical study of its lead compound SelG1 an antibody specific for the proinflammatory cell...
View ArticleSCOLR Pharma's Partner to Commence Bioequivalence Study of Ondansetron
BOTHELL Wash. Feb. 14 2012 PRNewswire SCOLR Pharma Inc. OTCQB SCLR announced today that RedHill Biopharma Ltd. a license partner that had previously obtained the exclusive worldwide rights to use...
View ArticlePsoriasis 2017 Report Updated 01072017 Prices from USD $8145
Will biosimilar antiTNFs prevent novel therapies from gaining traction As the use of biosimilar antiTNFs continues to expand access and lower the costs of biologic therapies in the treatment for...
View ArticleGlobal Crohn's Disease Partnering 2010 to 2017 Report Updated 01102017 Prices...
The Global Crohn's Disease Partnering Terms and Agreements since 2010 report provides understanding and access to partnering deals and agreements entered into by the world's leading healthcare...
View ArticleVolition Signs Collaboration Agreement With Abcodia
SINGAPORE Feb. 17 2012 PRNewswire &160;VolitionRX Limited VNRX.OB a life sciences company focused on developing bloodbased diagnostic tests announces a collaboration agreement with Abcodia a...
View ArticleSoligenix Announces Positive Survival Results of SGX202 in Radiation Injury
PRINCETON N.J. Feb. 21 2012 PRNewswire &160;Soligenix Inc. OTCBB SNGXD Soligenix or the Company a development stage biopharmaceutical company announced today further promising preliminary results...
View ArticleApplied Genetics Signs Marketing and Sales Agreement with Nutricion Avanzada
WESTMINSTER Colo. Feb. 22 2012 PRNewswire &160;GeneThera Inc. OTCQB GTHR announced today that Applied Genetics; GeneThera's majority owned subsidiary has entered in an exclusive marketing and sales...
View ArticleNektar to Announce Financial Results for the Fourth Quarter and YearEnd of...
SAN FRANCISCO Calif. Feb. 24 2012 PRNewswire &160;Nektar Therapeutics Nasdaq NKTR will announce its financial results for the fourth quarter ended December 31 2011 on Wednesday February 29 2012...
View ArticleNektar Therapeutics Announces Agreement to Sell CIMZIAÂ and MIRCERAÂ...
SAN FRANCISCO Feb. 29 2012 PRNewswire &160; Nektar Therapeutics Nasdaq NKTR today announced that it agreed to sell to Royalty Pharma its royalties on future sales of CIMZIA&174; under Nektar's...
View ArticleNektar Therapeutics Reports Fourth Quarter and YearEnd 2011 Financial Results
SAN FRANCISCO Feb. 29 2012 PRNewswire Nektar Therapeutics Nasdaq NKTR today reported its financial results for the fourth quarter and year ended December 31 2011. Cash cash equivalents and investments...
View Article